KATELYN SCAGNELLI: Open Payments
NPI 1760634943 · CHELMSFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 15 payments from 8 companies in 2025. Trend: 2023 $303 · 2024 $503 · 2025 $974
Food & beverage: $780Education: $194
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $279 |
| Astellas Pharma US Inc | 2 | $194 |
| JAZZ PHARMACEUTICALS INC. | 1 | $137 |
| Kite Pharma, Inc. | 1 | $129 |
| ABBVIE INC. | 1 | $98 |
| E.R. Squibb & Sons, L.L.C. | 1 | $95 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: RYBREVANT, ZIIHERA, EMRELIS, REBLOZYL, CARVYKTI, TECVAYLI, KISQALI, NINLARO.
Industry payments across MA — which companies pay providers there.
